Literature DB >> 7946796

ACE inhibitors for heart failure: a question of dose.

J G Cleland1, P A Poole-Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7946796      PMCID： PMC1025603          DOI： 10.1136/hrt.72.3_suppl.s106

Source DB:  PubMed          Journal:  Br Heart J        ISSN： 0007-0769


× No keyword cloud information.
  37 in total

Review 1.  Diverse factors influencing angiotensin metabolism during ACE inhibition: insights from molecular biology and genetic studies.

Authors:  K Morgan
Journal:  Br Heart J       Date:  1994-09

2.  Angiotensin-converting enzyme: vascular endothelial localization.

Authors:  P R Caldwell; B C Seegal; K C Hsu; M Das; R L Soffer
Journal:  Science       Date:  1976-03-12       Impact factor: 47.728

3.  Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.

Authors:  G A MacGregor; N D Markandu; J E Roulston; J C Jones
Journal:  Br Med J       Date:  1979-11-03

4.  Captopril treatment: inter-dose variations in renin, angiotensins I and II, aldosterone and blood pressure.

Authors:  A B Atkinson; A M Cumming; J J Brown; R Fraser; B Leckie; A F Lever; J J Morton; J I Robertson
Journal:  Br J Clin Pharmacol       Date:  1982-06       Impact factor: 4.335

5.  Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.

Authors:  J Cleland; P Semple; P Hodsman; S Ball; I Ford; H Dargie
Journal:  Am J Med       Date:  1984-11       Impact factor: 4.965

6.  Enalapril in patients with chronic heart failure: a placebo-controlled, randomized, double-blind study.

Authors:  D N Sharpe; J Murphy; R Coxon; S F Hannan
Journal:  Circulation       Date:  1984-08       Impact factor: 29.690

7.  Estimation of angiotensin II receptor activity in chronic congestive heart failure.

Authors:  R J Cody; A B Covit; G L Schaer; J H Laragh
Journal:  Am Heart J       Date:  1984-07       Impact factor: 4.749

8.  Enalapril maleate and a lysine analogue (MK-521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.

Authors:  J Biollaz; J L Schelling; B Jacot Des Combes; D B Brunner; G Desponds; H R Brunner; E H Ulm; M Hichens; H J Gomez
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

9.  Humoral and renal effects of MK-421 (enalapril) in hypertensive subjects.

Authors:  P W de Leeuw; R P Hoogma; G A van Soest; P T Tchang; W H Birkenhäger
Journal:  J Cardiovasc Pharmacol       Date:  1983 Sep-Oct       Impact factor: 3.105

10.  Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

Authors:  A B Atkinson; J J Morton; J J Brown; D L Davies; R Fraser; P Kelly; B Leckie; A F Lever; J I Robertson
Journal:  Br Heart J       Date:  1980-09
View more
  4 in total

Review 1.  Clinical case studies in heart failure management.

Authors:  R J MacFadyen; P Shiels; A D Struthers
Journal:  Br J Clin Pharmacol       Date:  1999-03       Impact factor: 4.335

Review 2.  Optimal treatment of heart failure in the elderly.

Authors:  R Doughty; V Andersen; N Sharpe
Journal:  Drugs Aging       Date:  1997-06       Impact factor: 3.923

Review 3.  Is aspirin safe for patients with heart failure?

Authors:  J G Cleland; C J Bulpitt; R H Falk; I N Findlay; C M Oakley; G Murray; P A Poole-Wilson; C R Prentice; G C Sutton
Journal:  Br Heart J       Date:  1995-09

Review 4.  The renin-angiotensin system and cardiac remodelling after acute myocardial infarction.

Authors:  H Ikram
Journal:  Heart       Date:  1996-11       Impact factor: 5.994
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.